Hepato-Immune Crosstalk Underlies Antipsychotic-Associated Metabolic Dysregulation in Schizophrenia: Quercetin as a Therapeutic Candidate for High-Inflammatory Subtypes.
- 1Shanghai Pudong New Area Mental Health Center (Tongji University Affiliated Mental Health Center), Tongji University Clinical Research Center for Mental Disorders, Shanghai 200124, China.
Abstract
Background: Patients with schizophrenia (SCZ) receiving antipsychotic treatment frequently develop metabolic complications, yet the mechanisms underlying liver-immune crosstalk remain poorly characterized. Methods: This study recruited 340 antipsychotic-treated SCZ patients and 340 matched healthy controls, with a 2-year follow-up restricted to the patient cohort. Candidate genes with hepatic metabolic relevance were screened from the independent GSE21138 brain transcriptomic dataset using machine learning. Molecular docking was performed to predict binding interactions of quercetin as a candidate bioactive compound. Results: Long-term antipsychotic exposure was associated with elevated serum 9-hydroxyrisperidone (9-OH-RISP) and substantial changes in liver function and metabolic markers; drug metabolite concentrations correlated with hepatic indices. Transcriptomic analysis identified 317 differentially expressed genes, from which 26 genes with liver-metabolism-related functions were selected as candidates. Seven hub genes (ABHD6, ALDH4A1, ETNPPL, etc.) were further identified via Support Vector Machine and Random Forest algorithms, and these genes were enriched in metabolic pathways, ferroptosis and other key signaling cascades. Unsupervised clustering based on hub gene expression stratified patients into high-inflammation (C2) and low-inflammation (C1) subtypes. The C2 subtype displayed computationally estimated enrichment of immune cells including B cells and naive CD8⁺ T cells. Molecular docking predicted strong binding affinity (binding energy ≤ -7.0 kcal/mol) between quercetin and proteins encoded by six hub genes, implying potential multi-target anti-inflammatory and metabolic-regulatory interactions. Conclusions: This study highlights the involvement of liver-immune crosstalk in antipsychotic-associated metabolic perturbations. The findings suggest exploratory potential for quercetin as a candidate bioactive compound in high-inflammatory SCZ subtypes, though these in silico predictions require further experimental validation.
Related
- Genetic Polymorphisms and Hemostatic-Inflammatory Biomarkers in Schizophrenia Patients Receiving Antipsychotic Treatment
- The LAI–Oral Antipsychotic Efficacy–Effectiveness Paradox in Schizophrenia
- Baseline severity of positive and negative symptoms predicts relapse in opposing directions among placebo-treated schizophrenia patients: analysis of five placebo-controlled, antipsychotic withdrawal, relapse-prevention trials
- Metabolic syndrome in stable long-term antipsychotic monotherapy and polypharmacy among patients with schizophrenia: a real-world comparative study.
- Sex differences in QTc prolongation and electrocardiographic changes before and after antipsychotic treatment of schizophrenia
BibTeX
@article{yang2026hepatoimmune,
title = {{Hepato-Immune Crosstalk Underlies Antipsychotic-Associated Metabolic Dysregulation in Schizophrenia: Quercetin as a Therapeutic Candidate for High-Inflammatory Subtypes.}},
author = {Yi Yang and Bin Liu and Zhicheng Cao and Haiping Fang and Yi Guo and Tingting Jiang and Ying Lu and Shumin Qu and Qiang Tang and Yingyi Wang and Ying Xia and Xirong Sun and Yiying Sun},
journal = {Metabolites},
year = {2026},
month = sep,
doi = {10.3390/metabo16100733},
url = {https://europepmc.org/article/MED/42941208},
note = {CC BY},
}
RIS
TY - JOUR
TI - Hepato-Immune Crosstalk Underlies Antipsychotic-Associated Metabolic Dysregulation in Schizophrenia: Quercetin as a Therapeutic Candidate for High-Inflammatory Subtypes.
AU - Yi Yang
AU - Bin Liu
AU - Zhicheng Cao
AU - Haiping Fang
AU - Yi Guo
AU - Tingting Jiang
AU - Ying Lu
AU - Shumin Qu
AU - Qiang Tang
AU - Yingyi Wang
AU - Ying Xia
AU - Xirong Sun
AU - Yiying Sun
PY - 2026
DA - 2026/09/29
JO - Metabolites
DO - 10.3390/metabo16100733
UR - https://europepmc.org/article/MED/42941208
AB - Background: Patients with schizophrenia (SCZ) receiving antipsychotic treatment frequently develop metabolic complications, yet the mechanisms underlying liver-immune crosstalk remain poorly characterized. Methods: This study recruited 340 antipsychotic-treated SCZ patients and 340 matched healthy controls, with a 2-year follow-up restricted to the patient cohort. Candidate genes with hepatic metabolic relevance were screened from the independent GSE21138 brain transcriptomic dataset using machine learning. Molecular docking was performed to predict binding interactions of quercetin as a candidate bioactive compound. Results: Long-term antipsychotic exposure was associated with elevated serum 9-hydroxyrisperidone (9-OH-RISP) and substantial changes in liver function and metabolic markers; drug metabolite concentrations correlated with hepatic indices. Transcriptomic analysis identified 317 differentially expressed genes, from which 26 genes with liver-metabolism-related functions were selected as candidates. Seven hub genes (ABHD6, ALDH4A1, ETNPPL, etc.) were further identified via Support Vector Machine and Random Forest algorithms, and these genes were enriched in metabolic pathways, ferroptosis and other key signaling cascades. Unsupervised clustering based on hub gene expression stratified patients into high-inflammation (C2) and low-inflammation (C1) subtypes. The C2 subtype displayed computationally estimated enrichment of immune cells including B cells and naive CD8⁺ T cells. Molecular docking predicted strong binding affinity (binding energy ≤ -7.0 kcal/mol) between quercetin and proteins encoded by six hub genes, implying potential multi-target anti-inflammatory and metabolic-regulatory interactions. Conclusions: This study highlights the involvement of liver-immune crosstalk in antipsychotic-associated metabolic perturbations. The findings suggest exploratory potential for quercetin as a candidate bioactive compound in high-inflammatory SCZ subtypes, though these in silico predictions require further experimental validation.
SN - 2218-1989
ER -